Chapter 27: Pharmacological Treatment of Respiratory Disorders

Pharmacological Treatment of Respiratory Disorders presentation explores the therapeutic landscape for managing respiratory ailments, specifically emphasizing the pathophysiology and treatment of asthma, chronic obstructive pulmonary disease (COPD), rhinitis, and cystic fibrosis. It distinguishes asthma as a condition of inflammatory-driven airway narrowing and heightened sensitivity to external triggers, requiring a combination of anti-inflammatory controllers and rapid-acting bronchodilators. Corticosteroids remain the primary defense against chronic inflammation, while selective beta2-adrenoceptor agonists provide essential relief for acute bronchospasm. The text delves into various classes of medications, including mast cell stabilizers for prevention, leukotriene receptor antagonists for oral maintenance, and long-acting bronchodilators for sustained airway patency. For patients with COPD, characterized by irreversible lung damage and mucus production, the roles of muscarinic antagonists and phosphodiesterase-4 inhibitors are highlighted as critical for reducing exacerbations. The chapter also provides a detailed look at methylxanthines like theophylline, noting the clinical importance of monitoring serum levels due to its narrow therapeutic window. Cutting-edge biological treatments, such as monoclonal antibodies that neutralize specific inflammatory mediators like IgE and interleukin-5, are discussed for managing severe, persistent cases. Beyond the lower respiratory tract, the summary covers antitussive agents for cough suppression, expectorants for mucus clearance, and multifaceted approaches to allergic rhinitis involving antihistamines and decongestants. Finally, it addresses the management of cystic fibrosis, detailing the use of mucolytics and innovative CFTR modulators that help correct underlying ion channel dysfunction to improve patient longevity and quality of life.